Category Archives: Warning Letters

Time for FDA’s OPDP to Fill the Gaps on Digital and Social Media

At mid-year, it has been a custom here at Eye on FDA to look back at a few categories of activity by FDA at the first half of the year and discern what it tells us about future directions. This … Continue reading

Posted in Warning Letters | Tagged | Comments Off on Time for FDA’s OPDP to Fill the Gaps on Digital and Social Media

OPDP Issues First Letter of the Year

Hey! 2009 called. They want their Warning Letter back! Last week FDA’s Office of Prescription Drug Promotion (OPDP) posted the first letter issued for 2020 that was sent in February for the most common violation of all – related to … Continue reading

Posted in Warning Letters | Comments Off on OPDP Issues First Letter of the Year

An Overview of FDA OPDP Enforcement for 2019

It is time to look back at enforcement for the 2019 year. It is still possible that FDA could post another letter, as there is a lag time between the time a letter is sent and the time it is … Continue reading

Posted in Warning Letters | Tagged , , | Comments Off on An Overview of FDA OPDP Enforcement for 2019

Enforcement Update – FDA OPDP Sends Two More Letters

For those who like to keep up on the activity of the Office of Prescription Drug Promotion (OPDP) here is an update. While not shaping up to be another big year of enforcement, there has been a bit of activity … Continue reading

Posted in Warning Letters | Comments Off on Enforcement Update – FDA OPDP Sends Two More Letters

FDA Sends CBD Related Warning Letter

This week FDA sent a Warning Letter to a company engaged in marketing products containing cannabidiol (CBD) to consumers for a wide variety of uses in both humans and canines. In addition to the letter, the agency underscored their action … Continue reading

Posted in CBD, FDA Policy, Warning Letters | Comments Off on FDA Sends CBD Related Warning Letter